# Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

Source: https://onco.cc/trials/nct07765836/  
OnCo record `nct07765836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of retifanlimab in pancreatic cancer, run by Massachusetts General Hospital, not yet recruiting.

## Summary

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC is a phase 2, interventional study registered as NCT07765836 by Massachusetts General Hospital, with a registry enrolment figure of 40 participants, started 2027-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: vilastobart (XTX101); Retifanlimab. Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: "* Participant must have histologically proven metastatic pancreatic cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: EKLAVYA-HRD
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07765836
- Phase: 2
- Setting: A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
- Sponsor: Massachusetts General Hospital
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07765836: https://clinicaltrials.gov/study/NCT07765836

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Retifanlimab](https://onco.cc/drugs/retifanlimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07765836.json